Spots Global Cancer Trial Database for checkpoint inhibitor
Every month we try and update this database with for checkpoint inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| TEIPP Immunotherapy in Patients With NSCLC | NCT05898763 | Non Small Cell ... | TEIPP24 (LRPAP7... | 18 Years - | Erasmus Medical Center | |
| Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas | NCT03172936 | Solid Tumors an... | MIW815 PDR001 | 18 Years - | Novartis | |
| Durvalumab Long-Term Safety and Efficacy Study | NCT04078152 | Solid Tumor | Durvalumab | 18 Years - 130 Years | AstraZeneca | |
| Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma | NCT02535078 | Malignant Melan... | Tebentafusp (IM... durvalumab tremelimumab | 18 Years - | Immunocore Ltd | |
| A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab | NCT04261439 | In Escalation: ... In Expansion: M... | NIZ985 Spartalizumab Tislelizumab | 18 Years - | Novartis | |
| Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC | NCT04507906 | NSCLC Stage IV Checkpoint Inhi... | Nivolumab Combi... | 18 Years - 75 Years | Shanghai Chest Hospital | |
| Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion | NCT06089369 | Hepatocellular ... | Sintilimab (9 c... Sintilimab (18 ... Active surveill... | 18 Years - 75 Years | Tongji Hospital | |
| Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy | NCT04283539 | Cancer | systemic cortic... | 18 Years - | National Jewish Health | |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | NCT03645928 | Metastatic Mela... Squamous Cell C... Non-small Cell ... | Lifileucel LN-145 Pembrolizumab LN-145-S1 Ipilimumab Nivolumab | 12 Years - | Iovance Biotherapeutics, Inc. | |
| A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer | NCT04267237 | Non-small Cell ... | Atezolizumab RO7198457 | 18 Years - | Hoffmann-La Roche | |
| A Study of PSB205 in Subjects With Advanced Solid Tumors | NCT03986606 | Neoplasm Malign... | PSB205 | 18 Years - | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | |
| A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer | NCT04267237 | Non-small Cell ... | Atezolizumab RO7198457 | 18 Years - | Hoffmann-La Roche | |
| Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma | NCT03116529 | Soft Tissue Sar... | Combination Rad... | 18 Years - | University of Maryland, Baltimore | |
| Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus | NCT03792347 | Esophageal Squa... | Pembrolizumab | 18 Years - 75 Years | Ruijin Hospital | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | NCT02439450 | Non-small Cell ... | Viagenpumatucel... Nivolumab Pembrolizumab Pemetrexed | 18 Years - | Heat Biologics | |
| A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | NCT02897765 | Urinary Bladder... Bladder Tumors Transitional Ce... Malignant Melan... Melanoma Skin Cancer Carcinoma, Non-... Lung Cancer | NEO-PV-01 Nivolumab Adjuvant | 18 Years - | BioNTech SE | |
| Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection | NCT04294498 | Advanced Hepato... | Durvalumab | 20 Years - | National Taiwan University Hospital | |
| Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma | NCT03644550 | Mesothelioma | LMB-100 Pembrolizumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) | NCT04009681 | Metastasis | THOR-707 Checkpoint inhi... anti-EGFR antib... | 18 Years - | Synthorx, Inc, a Sanofi company | |
| Derazantinib and Atezolizumab in Patients With Urothelial Cancer | NCT04045613 | Urothelial Carc... | Derazantinib 30... Derazantinib 20... Derazantinib 30... Derazantinib 20... Derazantinib 30... Derazantinib 30... Derazantinib 20... | 18 Years - | Basilea Pharmaceutica | |
| Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study | NCT04924062 | Biliary Tract C... | Pembrolizumab Gemcitabine Cisplatin Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects | NCT04861584 | Urinary Bladder... | Neoadjuvant Tor... | 18 Years - 75 Years | Zhujiang Hospital | |
| Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma | NCT03116529 | Soft Tissue Sar... | Combination Rad... | 18 Years - | University of Maryland, Baltimore | |
| Hemopurifier Plus Pembrolizumab in Head and Neck Cancer | NCT04453046 | Squamous Cell C... | Hemopurifier Pembrolizumab 2... | 18 Years - | Aethlon Medical Inc. | |
| Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC | NCT06173505 | Nonsquamous Non... | Vudalimab + Car... Pembrolizumab +... | 18 Years - | Xencor, Inc. | |
| A Study of PSB205 in Subjects With Advanced Solid Tumors | NCT03986606 | Neoplasm Malign... | PSB205 | 18 Years - | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | NCT03645928 | Metastatic Mela... Squamous Cell C... Non-small Cell ... | Lifileucel LN-145 Pembrolizumab LN-145-S1 Ipilimumab Nivolumab | 12 Years - | Iovance Biotherapeutics, Inc. | |
| Development and Analysis of a Stool Bank for Cancer Patients | NCT04291755 | Carcinoma, Non-... Carcinoma, Colo... | Pembrolizumab I... | 18 Years - | Persephone Biosciences | |
| Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer | NCT03658772 | Microsatellite ... | grapiprant grapiprant and ... | 18 Years - | Arrys Therapeutics | |
| Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | NCT03301896 | Solid Tumors | LHC165 PDR001 | 18 Years - | Novartis | |
| A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma | NCT03597282 | Metastatic Mela... | NEO-PV-01 Nivolumab Adjuvant APX005M ipilimumab | 18 Years - | BioNTech SE | |
| Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA) | NCT02565992 | Melanoma | CAVATAK Pembrolizumab | 18 Years - | Viralytics | |
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | NCT03841110 | Advanced Solid ... Lymphoma Gastric Cancer Colorectal Canc... Head and Neck C... Squamous Cell C... EGFR Positive S... HER2-positive B... Hepatocellular ... Small Cell Lung... Renal Cell Carc... Pancreas Cancer Melanoma NSCLC Urothelial Carc... Cervical Cancer Microsatellite ... Merkel Cell Car... | FT500 Nivolumab Pembrolizumab Atezolizumab Cyclophosphamid... Fludarabine IL-2 | 18 Years - | Fate Therapeutics | |
| Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. | NCT05243862 | Colorectal Canc... | PolyPEPI1018 Atezolizumab | 18 Years - | Treos Bio Limited | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma | NCT04840615 | Mesothelioma | LMB-100 ipilimumab Diphenhydramine Famotidine Acetaminophen Dexamethasone Biopsy FDG-PET CT CAP MRI ECG Echocardiogram | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | NCT02439450 | Non-small Cell ... | Viagenpumatucel... Nivolumab Pembrolizumab Pemetrexed | 18 Years - | Heat Biologics | |
| Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer | NCT03906071 | Metastatic Non-... | Nivolumab Sitravatinib Docetaxel | 18 Years - | Mirati Therapeutics Inc. | |
| Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937) | NCT03867084 | Hepatocellular ... | Pembrolizumab Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) | NCT04009681 | Metastasis | THOR-707 Checkpoint inhi... anti-EGFR antib... | 18 Years - | Synthorx, Inc, a Sanofi company | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | NCT05000294 | Bile Duct Cance... Gall Bladder Ca... Breast Cancer Neuroendocrine ... Ovarian Cancer Pancreatic Aden... Soft Tissue Sar... Vulvar Cancer Prostate Cancer | Atezolizumab Tivozanib | 18 Years - 99 Years | University of Florida | |
| A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab | NCT04261439 | In Escalation: ... In Expansion: M... | NIZ985 Spartalizumab Tislelizumab | 18 Years - | Novartis | |
| Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma | NCT04949113 | Malignant Melan... | Neoadjuvant ipi... Adjuvant nivolu... | 16 Years - | The Netherlands Cancer Institute | |
| A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients | NCT05561491 | Melanoma | ONCOS-102 Balstilimab | 18 Years - | Targovax ASA | |
| Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) | NCT04003636 | Biliary Tract C... | Pembrolizumab Gemcitabine Cisplatin Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA) | NCT06074692 | Sarcoma Sarcoma,Soft Ti... Sarcoma of Bone | Camrelizumab an... | 10 Years - 70 Years | Ruijin Hospital | |
| ARGONAUT: Stool and Blood Sample Bank for Cancer Patients | NCT04638751 | Non-small Cell ... Colorectal Canc... Triple Negative... Pancreas Cancer | Immunotherapy Chemotherapy CRC surgical re... Colonoscopy | 18 Years - | Persephone Biosciences | |
| Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC | NCT04507906 | NSCLC Stage IV Checkpoint Inhi... | Nivolumab Combi... | 18 Years - 75 Years | Shanghai Chest Hospital | |
| INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) | NCT03491683 | Glioblastoma | INO-5401 INO-9012 Cemiplimab Radiation Thera... Temozolomide | 18 Years - | Inovio Pharmaceuticals | |
| A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients | NCT05561491 | Melanoma | ONCOS-102 Balstilimab | 18 Years - | Targovax ASA | |
| A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab | NCT04261439 | In Escalation: ... In Expansion: M... | NIZ985 Spartalizumab Tislelizumab | 18 Years - | Novartis | |
| A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer | NCT03380871 | Carcinoma, Non-... Lung Cancer Nonsquamous Non... | NEO-PV-01 Pembrolizumab Adjuvant Carboplatin Pemetrexed | 18 Years - | BioNTech SE | |
| Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07). | NCT04068181 | Melanoma | Talimogene lahe... Pembrolizumab | 18 Years - 99 Years | Amgen | |
| Checkpoint Inhibitors in Patients With Solid Tumors: a Retrospective Real-world Study | NCT05719324 | Immunotherapy | 18 Years - | The First Affiliated Hospital with Nanjing Medical University | ||
| 9-ING-41 in Patients With Advanced Cancers | NCT03678883 | Cancer Pancreatic Canc... Sarcoma Renal Cancer Refractory Canc... Refractory Neop... Refractory Non-... Pancreatic Aden... Resistant Cance... Neoplasm Metast... Neoplasm of Bon... Neoplasm, Breas... Neoplasm of Lun... Neoplasms,Color... Neoplasms Pancr... Malignant Gliom... Malignancies Malignancies Mu... Bone Metastases Bone Neoplasm Bone Cancer Pancreas Cancer Pancreatic Neop... Breast Neoplasm... Acute T Cell Le... | 9-ING-41 Gemcitabine - 2... Doxorubicin. Lomustine Carboplatin. Nab paclitaxel. Paclitaxel. Gemcitabine - 2... Irinotecan | 18 Years - | Actuate Therapeutics Inc. | |
| Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer | NCT05177770 | Metastatic Cast... Prostate Cancer | SRF617 etrumadenant zimberelimab | 18 Years - | Coherus Biosciences, Inc. | |
| Breast Cancer Study of Preoperative Pembrolizumab + Radiation | NCT03366844 | Breast Cancer | Pembrolizumab RT Boost | 18 Years - | Cedars-Sinai Medical Center | |
| Breast Cancer Study of Preoperative Pembrolizumab + Radiation | NCT03366844 | Breast Cancer | Pembrolizumab RT Boost | 18 Years - | Cedars-Sinai Medical Center | |
| Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma | NCT03644550 | Mesothelioma | LMB-100 Pembrolizumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Checkpoint Inhibitors in Patients With Cancer and Underlying Autoimmune Disease | NCT04805099 | Autoimmune Dise... Checkpoint Inhi... Immunotherapy | Checkpoint inhi... | 18 Years - | Hellenic Cooperative Oncology Group | |
| A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | NCT04042116 | Advanced Solid ... Gynecologic Can... | Lucitanib Lucitanib Lucitanib Nivolumab | 18 Years - | Clovis Oncology, Inc. | |
| Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) | NCT04574583 | Metastatic Canc... Solid Tumors | SX-682 M7824 MVA-BN-CV301 recombinant fow... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma | NCT04995120 | Laryngeal Cance... Hypopharynx Can... Laryngeal Neopl... | chemotherapy TP... | 18 Years - 75 Years | Fudan University | |
| Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers | NCT03388632 | Metastatic Soli... Treatment-Refra... | rhIL-15 Ipilimumab Nivolumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Combination Immunotherapy in Biochemically Recurrent Prostate Cancer | NCT03315871 | Prostate Cancer | PROSTVAC-V PROSTVAC-F MSB0011359C (M7... CV301 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation | NCT04104893 | Metastatic Cast... | Pembrolizumab | 18 Years - | VA Office of Research and Development | |
| A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | NCT04042116 | Advanced Solid ... Gynecologic Can... | Lucitanib Lucitanib Lucitanib Nivolumab | 18 Years - | Clovis Oncology, Inc. | |
| LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | NCT04027946 | Lung Cancer Non-Small Cell ... Adenocarcinoma ... | LMB-100 pembrolizumab Mesothelin Expr... TrueSight Oncol... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer | NCT05177770 | Metastatic Cast... Prostate Cancer | SRF617 etrumadenant zimberelimab | 18 Years - | Coherus Biosciences, Inc. | |
| Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence | NCT04410445 | Melanoma Melanoma Stage ... Melanoma Stage ... Melanoma (Skin) | Bempegaldesleuk... Nivolumab | 12 Years - | Nektar Therapeutics | |
| A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation | NCT04104893 | Metastatic Cast... | Pembrolizumab | 18 Years - | VA Office of Research and Development | |
| Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer | NCT05472506 | Head and Neck S... Head and Neck C... Head Cancer Neck Cancer Head Cancer Nec... Neck Carcinoma | IK-175 + nivolu... | 18 Years - | Ikena Oncology | |
| Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma | NCT04526899 | Melanoma Stage ... Melanoma Stage ... Unresectable Me... | BNT111 Cemiplimab | 18 Years - | BioNTech SE | |
| Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas | NCT03172936 | Solid Tumors an... | MIW815 PDR001 | 18 Years - | Novartis | |
| Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant | NCT03966209 | Hepatocellular ... Liver Transplan... | JS001(PD-1 inhi... | 18 Years - 70 Years | Shanghai Zhongshan Hospital | |
| Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07). | NCT04068181 | Melanoma | Talimogene lahe... Pembrolizumab | 18 Years - 99 Years | Amgen | |
| Derazantinib and Atezolizumab in Patients With Urothelial Cancer | NCT04045613 | Urothelial Carc... | Derazantinib 30... Derazantinib 20... Derazantinib 30... Derazantinib 20... Derazantinib 30... Derazantinib 30... Derazantinib 20... | 18 Years - | Basilea Pharmaceutica | |
| A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors | NCT06188208 | Advanced Solid ... Advanced Hemato... | VVD-130850 Pembrolizumab | 18 Years - | Vividion Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
